Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma Intervention: Drug: [212Pb]VMT-α-NET, Sponsor: Viewpoint Molecular Targeting Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma; Paraganglioma Intervention: Drug: [18F]FluorThanatrace ([18F]FTT) Sponsor: Heather Wachtel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma Intervention: Drug: [212Pb]VMT-α-NET, Sponsor: Viewpoint Molecular Targeting Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma; Paraganglioma Intervention: Drug: [18F]FluorThanatrace ([18F]FTT) Sponsor: Heather Wachtel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma Intervention: Drug: [212Pb]VMT-α-NET, Sponsor: Viewpoint Molecular Targeting Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma; Paraganglioma Intervention: Drug: [18F]FluorThanatrace ([18F]FTT) Sponsor: Heather Wachtel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma Intervention: Drug: [212Pb]VMT-α-NET, Sponsor: Viewpoint Molecular Targeting Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma; Paraganglioma Intervention: Drug: [18F]FluorThanatrace ([18F]FTT) Sponsor: Heather Wachtel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2022 Category: Research Source Type: clinical trials
